• Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK (from parent cell line).
  

PubMed=21502504; DOI=10.1073/pnas.1019559108; PMCID=PMC3088626
Katayama R., Khan T.M., Benes C.H., Lifshits E., Ebi H., Rivera V.M., Shakespeare W.C., Iafrate A.J., Engelman J.A., Shaw A.T.
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Proc. Natl. Acad. Sci. U.S.A. 108:7535-7540(2011)

PubMed=23344087; DOI=10.1097/JTO.0b013e318283dcc0
Kim S., Kim T.M., Kim D.-W., Go H., Keam B., Lee S.-H., Ku J.-L., Chung D.H., Heo D.S.
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
J. Thorac. Oncol. 8:415-422(2013)

PubMed=24675041; DOI=10.1158/2159-8290.CD-13-0846; PMCID=PMC4068971
Friboulet L., Li N.-X., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., Michellys P.-Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C., Li J., Kasibhatla S., Sun F., Sun X.-Y., Hua S., McNamara P., Mahmood S., Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T., Engelman J.A.
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Cancer Discov. 4:662-673(2014)